Secondary Logo

Institutional members access full text with Ovid®

Advances in dry eye disease treatment

O’Neil, Erin C.; Henderson, Matthew; Massaro-Giordano, Mina; Bunya, Vatinee Y.

Current Opinion in Ophthalmology: May 2019 - Volume 30 - Issue 3 - p 166–178
doi: 10.1097/ICU.0000000000000569
TRANSLATIONAL RESEARCH: Edited by Jason Hsu and Sunir J. Garg
Buy
SDC

Purpose of review The prevalence and burden of dry eye disease continues to grow at a rapid pace, creating an increased need for new therapies. In a sector once limited to only a handful of treatments, clinicians now have multiple options available for patients who fail traditional therapies. This review summarizes the various treatment options available to clinicians treating complex dry eye disease patients.

Recent findings As we better understand the multifactorial mechanisms leading to dry eye disease, treatments increasingly focus on the amelioration of the underlying deficiencies and inflammation, rather than on transient symptomatic relief alone. Most topical medications seek to replace deficient growth factors and/or decrease inflammation on the ocular surface. The majority of new devices and procedures seek to treat meibomian gland dysfunction, with one new device stimulating tear production through utilizing the nasolacrimal reflex pathway.

Summary Clinicians have more options at their disposal in the treatment of dry eye disease than ever before, including topical medications and devices.

Scheie Eye Institute, University of Pennsylvania, Philadelphia, USA

Correspondence to Vatinee Y. Bunya, MD, Scheie Eye Institute, University of Pennsylvania, 51 N. 39th Street, Philadelphia, PA 19104, USA. Tel: +1 215 662 9791; fax: +1 215 243 4695; e-mail: vatinee.bunya@uphs.upenn.edu

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.